SG Americas Securities LLC raised its position in OPKO Health, Inc. (NASDAQ:OPK – Get Rating) by 9.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 150,086 shares of the biotechnology company’s stock after purchasing an additional 12,542 shares during the period. SG Americas Securities LLC’s holdings in OPKO Health were worth $188,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently modified their holdings of OPK. Cetera Advisor Networks LLC lifted its position in shares of OPKO Health by 33.7% during the 1st quarter. Cetera Advisor Networks LLC now owns 15,156 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 3,820 shares during the period. Creative Planning lifted its position in shares of OPKO Health by 4.6% during the 2nd quarter. Creative Planning now owns 89,210 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 3,963 shares during the period. Captrust Financial Advisors lifted its position in shares of OPKO Health by 13.3% during the 2nd quarter. Captrust Financial Advisors now owns 38,847 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 4,573 shares during the period. Forum Financial Management LP lifted its position in shares of OPKO Health by 48.5% during the 1st quarter. Forum Financial Management LP now owns 17,043 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 5,569 shares during the period. Finally, ProShare Advisors LLC lifted its position in shares of OPKO Health by 16.7% during the 4th quarter. ProShare Advisors LLC now owns 51,950 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 7,444 shares during the period. Institutional investors and hedge funds own 23.49% of the company’s stock.
OPKO Health Stock Performance
Shares of OPK stock opened at $1.72 on Friday. The firm has a market capitalization of $1.33 billion, a PE ratio of -4.53 and a beta of 1.68. The firm has a fifty day simple moving average of $1.45 and a two-hundred day simple moving average of $1.41. The company has a current ratio of 1.83, a quick ratio of 1.49 and a debt-to-equity ratio of 0.14. OPKO Health, Inc. has a 12 month low of $1.00 and a 12 month high of $3.24.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on OPK shares. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, March 9th. LADENBURG THALM/SH SH decreased their price target on shares of OPKO Health from $5.75 to $5.40 in a research note on Thursday, May 4th. Finally, StockNews.com began coverage on shares of OPKO Health in a research note on Thursday, March 16th. They set a “sell” rating for the company.
Insider Transactions at OPKO Health
In other news, insider Gary J. Nabel bought 187,608 shares of OPKO Health stock in a transaction dated Friday, May 5th. The stock was purchased at an average price of $1.81 per share, for a total transaction of $339,570.48. Following the purchase, the insider now directly owns 263,079 shares in the company, valued at approximately $476,172.99. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Gary J. Nabel purchased 187,608 shares of the business’s stock in a transaction that occurred on Friday, May 5th. The shares were bought at an average cost of $1.81 per share, with a total value of $339,570.48. Following the acquisition, the insider now owns 263,079 shares of the company’s stock, valued at $476,172.99. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Phillip Md Et Al Frost purchased 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 22nd. The stock was bought at an average cost of $1.32 per share, for a total transaction of $264,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 200,031,694 shares in the company, valued at approximately $264,041,836.08. The disclosure for this purchase can be found here. Insiders bought a total of 1,387,608 shares of company stock worth $1,783,570 in the last quarter. 40.97% of the stock is currently owned by corporate insiders.
OPKO Health Profile
OPKO Health, Inc is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations.
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.